Please assess the completion status of the following clinical trial:

Trial Title: A Phase 2 Study of SP-02L in Patients With Relapsed or Refractory Peripheral T-cell Lymphoma (PTCL)

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Patients with a Japanese, Korean, Taiwanese, or Chinese ethnic background of each country/region~* Patients aged ≥20 years on the date of informed consent~* Patients with histologically confirmed diagnosis of one of the following:~  * Peripheral T-cell lymphoma not otherwise specified (PTCL-NOS)~ * Angioimmunoblastic T-cell Lymphoma (AITL)~ * Anaplastic large cell lymphoma (ALCL), (ALK-positive/negative)~* Relapsed or refractory patients with a treatment history of at least one regimen with antitumor agents for the above disease~* Have at least 1 measurable lesion~* Eastern Cooperative Oncology Group (ECOG) performance status of 0 to 2~* Patients with a life expectancy of at least 3 months as determined by the investigator

- Gender: ALL
- Minimum Age: 20 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- SP-02L (darinaparsin for injection) (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).